Mostrando 10 resultados de: 15
Filtros aplicados
CYP2D6 and the severity of suicide attempts
ArticleAbstract: Aim: Among people who die by suicide, an increased frequency of CYP2D6 active gene multiplication haPalabras claves:CYP2D6, severity of suicide attempt, ultrarapid metabolizerAutores:Adrián LLerena, Baca-Garca E., Blasco-Fontecilla H., Dorado P., Penãs-Lledó E.M., Vaquero-Lorenzo C.Fuentes:scopusCYP2D6 genetic polymorphisms in Southern Mexican Mayan Lacandones and Mestizos from Chiapas
ArticleAbstract: Aim: In previous CYP2D6 genotyping studies in Mexican-Amerindians a very low frequency of poor metabPalabras claves:CYP2D6, Lacandones, Mexican-Mestizo, pharmacogeneticsAutores:Adrián LLerena, Alonso E., Dorado P., López-López M., Ochoa-Morales A., Ortega A., Penãs-Lledó E.M., Vázquez T.C., Yescas-Gómez P.Fuentes:scopusCYP2D6 polymorphism: Implications for antipsychotic drug response, schizophrenia and personality traits
ReviewAbstract: The CYP2D6 gene is highly polymorphic, causing absent (poor metabolizers), decreased, normal or incrPalabras claves:Adverse side effects, antipsychotics, CYP2D6, personality, pharmacogenetics, Pharmacogenomics, QTc, Schizophrenia, vulnerabilityAutores:Adrián LLerena, Dorado P., Penãs-Lledó E.M.Fuentes:scopusCYP2D6-1584C>G promoter polymorphism and debrisoquine ultrarapid hydroxylation in healthy volunteers
ArticleAbstract: Background & aim: The CYP2D6-1584C>G polymorphism (rs1080985) has been identified as a major factorPalabras claves:1584C>G, CYP2D6, debrisoquine, Healthy volunteers, ultrarapid metabolismAutores:Adrián LLerena, Alvárez M., Calzadilla L.R., Dorado P., González I., Naranjo M.E.G., Penãs-Lledó E.M., Pérez B., Ramirez R.Fuentes:scopusAllele and genotype frequencies of genes relevant to anti-epileptic drug therapy in Mexican-Mestizo healthy volunteers
ArticleAbstract: Aim: To determine allele and genotype frequencies of genes influencing anti-epileptic drug therapy iPalabras claves:ABCC2, anti-epileptics, CYP3A5, EPHX1, GABRA1, HNF4A, Mexican-Mestizo, NR1I2, pharmacogenetics, RALBP1, SCN1A, SCN2A, UGT1A1, UGT2B7Autores:Adrián LLerena, Dorado P., Fricke-Galindo I., Jung-Cook H., López-López M., Monroy-Jaramillo N., Ortega-Vázquez A., Penãs-Lledó E.M.Fuentes:scopusLosartan hydroxylation phenotype in an Ecuadorian population: Influence of CYP2C9 genetic polymorphism, habits and gender
ArticleAbstract: Aim: To describe for the first time CYP2C9 hydroxylation phenotype with CYP2C9 genotypes in a HispanPalabras claves:CYP2C9 genotype, CYP2C9 hydroxylation, Ecuadorians, Hispanics, LOSARTÁNAutores:Adrián LLerena, Dorado P., Enrique Terán, Leonardo J. Beltrán, Machín E., Penãs-Lledó E.M.Fuentes:scopusPharmacogenetic research activity in Central America and the Caribbean: A systematic review
ReviewAbstract: Aim: The present review was aimed at analyzing the pharmacogenetic scientific activity in Central AmPalabras claves:Biomarkers, Caribbean Region, Central America, pharmacogenetics, PharmacogenomicsAutores:Adrián LLerena, Campos M.D.L.A., Céspedes-Garro C., Duconge J., Humberto Fariñas, Montané-Jaime L.K., Naranjo M.E.G., Penãs-Lledó E.M., Ramirez R., Roblejo H., Rodrigues-Soares F., Serrano V., Villagrán C.I.Fuentes:scopusPharmacogenetics of clinical response to risperidone
ReviewAbstract: Despite risperidones proven safety and efficacy, existing pharmacogenetic knowledge could be appliedPalabras claves:Biomarkers, Clinical outcome, pharmacogenetics, Risperidone, side effectsAutores:Adrián LLerena, Berecz R., Humberto Fariñas, Penãs-Lledó E.M., Süveges A.Fuentes:scopusPharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity
ReviewAbstract: Debrisoquine hydroxylation polymorphism is by far the most thoroughly studied genetic polymorphism oPalabras claves:CYP2D6, Cytochrome p450, debrisoquine, PharmacogenomicsAutores:Adrián LLerena, Dorado P., Penãs-Lledó E.M.Fuentes:scopusRelation between CYP2D6 genotype, personality, neurocognition and overall psychopathology in healthy volunteers
Conference ObjectAbstract: Aims: A lower serotonin/higher dopamine tone in CYP2D6 poor metabolizers (PMs) versus extensive metaPalabras claves:CANTAB®, CYP2D6, Impulsivity, KSP, personality, pharmacogenetics, Pharmacogenomics, SCL-90-R, TCI-RAutores:Adrián LLerena, Dorado P., González I., Pacheco R., Penãs-Lledó E.M.Fuentes:scopus